Merck’s Diabetes Dominance at Risk as Rival Drug Helps Out Heart
This article is for subscribers only.
Diabetes isn’t looking as good as it used to for Merck & Co.
Just two months after the company celebrated a study showing that its best-selling diabetes drug Januvia didn’t harm the heart, new research shows a rival pill significantly reduces the risk of cardiac events -- a first for any diabetes drug.